« Previous Next » Cancer Letters
Volume 238, Issue 2 , Pages 197-201 , 18 July 2006

Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model

Miaorong She
- Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
- Dr. M. She is a visiting scholar from the Department of Hematology, Guangdong Provincial People's Hospital, Guangzhou, People's Republic of China.
Sai-Ching Jim Yeung
- Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
- Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
- Corresponding author. Address: The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 437, Houston, TX 77030, USA. Tel.: +1 713 745 4516.

Received 30 October 2004 ,Accepted 5 July 2005.

References

K.B. Ain, Anaplastic thyroid carcinoma: a therapeutic challenge, 16 (1999) 64–69.
S. Yeung, G. Xu, J. Pan, M. Christgen, A. Bamiagis, Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells, 60 (2000) 650–656.
G. Xu, J. Pan, C. Martin, C. Yeung, Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma, 86 (2001) 1769–1777.
W.Z. Gu, S.K. Tahir, Y.C. Wang, H.C. Zhang, S.P. Cherian, S. O'Connor, J.A. Leal, S.H. Rosenberg, C. Ng, Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo, 35 (1999) 1394–1401.
M.M. Feldkamp, N. Lau, A. Guha, Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects, 18 (1999) 7514–7526.
J.A. Fagin, K. Matsuo, A. Karmakar, D.L. Chen, S.H. Tang, P. Koeffler, High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas, 91 (1993) 179–184.
A. Yoshida, M. Fukazawa, H. Ushio, Y. Aiyoshi, S. Soeda, K. Ito, Study of cell kinetics in anaplastic thyroid carcinoma transplanted to nude mice, 41 (1989) 1–4.
R. Sposto, D.O. Stram, A strategic view of randomized trial design in low-incidence paediatric cancer, 18 (1999) 1183–1197.
N. Strauss, R. Simon, Investigating a sequence of randomized phase II trials to discover promising treatments, 14 (1995) 1479–1489.
E.A. Sotomayor, B.A. Teicher, G.N. Schwartz, S.A. Holden, K. Menon, T.S. Herman, E. Frei, 3rd, Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo, 30 (1992) 377–384.
B.A. Teicher, S.A. Holden, N.P. Dupuis, Y. Kakeji, M. Ikebe, Y. Emi, D. Goff, Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma, 36 (1995) 227–236.
Y. Kakeji, A. Teicher, Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents, 15 (1997) 39–48.